Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 4/20 | 0.31 |
| ▸ | JAK3 | P52333 | 4/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061357 | 1.00 | KMT2A (0.33) | KMT2AMEN1PDE4DTDP1ADORA3 | |
| SCHEMBL23068546 | 1.00 | KMT2A (0.33) | KMT2AMEN1PDE4DTDP1ADORA3 | |
| SCHEMBL23068541 | 0.93 | JAK3 (0.36) | KMT2ATDP1ADORA3JAK2JAK3 | |
| SCHEMBL21061348 | 0.93 | JAK3 (0.36) | KMT2ATDP1ADORA3JAK2JAK3 | |
| SCHEMBL23068542 | 0.93 | JAK3 (0.36) | KMT2ATDP1ADORA3JAK2JAK3 | |
| SCHEMBL20851937 | 0.90 | JAK3 (0.40) | KMT2AMEN1ADORA3JAK2JAK3 | |
| SCHEMBL20838977 | 0.90 | JAK3 (0.40) | KMT2AMEN1ADORA3JAK2JAK3 | |
| SCHEMBL20838962 | 0.90 | JAK3 (0.40) | KMT2AMEN1ADORA3JAK2JAK3 | |
| SCHEMBL23084516 | 0.88 | JAK2 (0.42) | KMT2AMEN1PDE4DTDP1JAK2 | |
| SCHEMBL21098225 | 0.88 | JAK2 (0.42) | KMT2AMEN1PDE4DTDP1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | KMT2A 2334/4885MEN1 2445/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.